Archimedes Pharma announced that Lazanda (fentanyl nasal spray) is available for the management of breakthrough pain in cancer patients ≥18 years who are already receiving and who are tolerant to opioid therapy for their underlying persistent cancer pain. Lazanda uses Archimedes’ patented PecSys drug delivery system. Each spray of Lazanda forms a gel when it contacts the nasal mucosa; the active ingredient is then rapidly absorbed across the mucus membrane and directly into the blood stream.
Lazanda is a Schedule II controlled substance and is available through a Risk Evaluation and Mitigation Strategy (REMS) program. Under the Lazanda REMS program, pharmacies, distributors, and health care professionals who prescribe to outpatients are required to enroll in the program to dispense, distribute, and prescribe Lazanda.
For more information call (866) 435-6775 or visit www.lazanda.com.